HIVPediatrics
Meeting category
Date(s)
16 Jul 2021 - 17 Jul 2021
Meeting type
Virtual Meeting
Organizer

International Workshop on HIV Pediatrics 2021

Related Enduring Materials

Enduring Materials

All times below are in Eastern Daylight Time (EDT). 

Download the Program Book 

Download the Group Photo

Day 1 - Friday, 16 July 2021
On Demand Youth Panel -
MUST WATCH - Adolescents in conversation with Dr. Caroline Foster talking about PrEP – including long-acting injectables
Saidy Brown
South Africa
Tony Ramirez
United States
Xavier Ramos
United States
Munkh-Erdene Davaajav
Mongolia
Session 1: Global Updates -
The HIV Epidemic in Infants, Children, Adolescents and Women Today – 2021 UNAIDS Update
Mary Mahy, ScD, MHSc
UNAIDS, Switzerland
Pediatric HIV Treatment and Prevention: What’s New for 2021
Session 2: Oral Abstract Presentations - 3 Parallel Sessions -
Pediatric Treatment
Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the Smile PENTA-17 Trial
#1 - Alexandra Compagnucci, France
B/F/Taf in Virologically Suppressed Adolescents and Children: Two- Year Outcomes in 6 to <18 Year Olds And Six-Month Outcomes in Toddlers
#2 - Eva Natukunda, Uganda
Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 Kg: Preliminary Results from IMPAACT 2019
#3 - Kristina Brooks, United States
Long-Term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Fumarate (E/C/F/TAF) Single-Tablet Regimen In Children and Adolescents Living With HIV
#4 - Suvaporn Anugulruengkitt, Thailand
Pharmacokinetics, Safety and Acceptability of a Single Dose of Abacavir/Lamivudine/Lopinavir/Ritonavir (4-In-1) Fixed-Dose Granule Formulation In Neonates: PETITE Study
#5 - Tim Cressey, Thailand
Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South Africa
#6 - Isaac Ravi Brenner, United States
LATE BREAKER - Dolutegravir-Based Art is Superior to Standard of Care in Young Children Living With HIV
#124 - Pauline Amuge, Uganda
Complications of Pediatric or Maternal ART
Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial
#7 - Hilda Angela Mujuru, Zimbabwe
Dolutegravir and Weight Gain to Adolescents Living with HIV at Baylor Mwanza-Tanzania
#8 - Esther Masunga, Tanzania
Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South Africa
#9 - Claire Davies, South Africa
Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of- Care in the ODYSSEY Trial
#10 - Cissy Kityo, Uganda
Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South Africa
#11 - Amy Slogrove, South Africa
Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF Vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 Trial
#12 - Tapiwa Mbengeranwa, Zimbabwe
Impact of COVID-19 Pandemic on Pediatric HIV
Impact of the COVID-19 Pandemic on Perinatal HIV Prevention in Canada: Canadian Perinatal HIV Surveillance Program
#13 - Joel Singer, Canada
A Comparative Multi-Country Analysis of the Impact of COVID-19 on HIV Services for Pregnant and Breastfeeding Women and Their Infants
#14 - Alexandra Vrazo, United States
Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries
#15 - Elizabeth Rabold, United States
The Impact of COVID-19 on HIV Services for Children Living with HIV Across 14 Countries
#16 - Megan Gleason, United States
Pediatric and Adolescent HIV Viral Load Coverage and Suppression Rates in the Context of the COVID-19 Pandemic in 14 Sub-Saharan African PEPFAR Countries in 2019 and 2020
#17 - Deborah Carpenter, United States
Knowledge and Perceptions of Covid-19 Among Young People Living With HIV in Malawi and the Impact of the Pandemic on Their Health and Wellbeing
#18 - Kajal Hirani, Malawi
Session 3: Clinical Case Presentations -
Case Presentation 1
Katie Simon, MD
Baylor Children's Clinical Centre of Excellence, Malawi
Case Presentation 2
Katherine Hsu, MD, MPH, FAAP
Boston University Medical Center, United States
Commenters on Cases
Nadia Sam-Agudu, MD, CTropMed
University of Minnesota / Institute of Human Virology Nigeria, United States / Nigeria
Thanyawee Puthanakit, MD
Chulalongkorn University, Thailand
Sharon Nachman, MD
SUNY Health Science Center Stony Brook / IMPAACT Network, United States
Session 4: Guided Poster Tours - 4 Parallel Sessions -
Guided Poster Tour 1 - Prevention of Perinatal HIV Transmission
Strategies Used in Countries With Successful Mother-Infant Pair Tracking
#37 - Aimee Rurangwa, United States
Participatory PMTCT: Community Engagement For Co-Created PMTCT Programming in 2 Districts of Zimbabwe
#38 - Electa Mutyambizi, Zimbabwe
Population-Level Risk Factors For Vertical Transmission of HIV Within the National Prevention of Mother-To-Child Transmission Programme in South Africa: An Ecological Analysis
#39 - Faith Moyo, South Africa
Risk Factors For Adverse Pregnancy Outcomes Among Pregnancy Women Living With HIV on ART
#40 - Wenwen Jiang, United States
Barriers to Early Infant Diagnosis (EID) at Different Stages of Infancy
# 41 - Linda Ndlovu, South Africa
Guided Poster Tour 2 - Pregnancy and HIV
Pregnancy Characteristics and Outcomes Among Migrant Women Living With HIV Recently Arrived in the UK
#42 - Rowan Eastabrook, United Kingdom
Factors Associated With Recent HIV Infection Among Pregnant Women in Lilongwe, Malawi: A Case Control Study
#43 - Hanna Huffstetler, United States
Prevalence of Depression Among Postpartum Women on Isoniazid- Preventive Therapy and Efavirenz-Based Treatment For HIV—An Exploratory Objective of the IMPAACT P1078 Randomized Trial
#44 - Patricia Mandima, Zimbabwe
Trends in Characteristics and Care Of Women Diagnosed With HIV During Pregnancy in the UK
#45 - Rebecca Sconza, United Kingdom
Feasibility and Acceptability of Administering the Cross Culturally Adapted ACTG Adherence Questionnaire to Ugandan Women Living With HIV Via Audio Computer Assisted Self Interview (ACASI) vs Via Provider-Assisted Interview
#46 - Patience Atuhaire, Uganda
Guided Poster Tour 3 - Pediatric Treatment and Care
Behavioural and Emotional Outcomes at 7 and 9 Years in Children From the Children With HIV Early Antiretroviral (CHER) Trial: A Longitudinal Investigation
#47 - Kaylee van Wyhe, South Africa
An Assessment of Multi-Month Dispensing of Antiretroviral Therapy For Children and Adolescents Across 10 African Countries
#48 - Ashley Sorgi, United States
A Systematic Review and Meta-Analysis of HIV Risk Screening Tools to Identify At-Risk Children and Adolescents For HIV Testing
#49 - Nimasha Fernando, United States
Effect of HIV on the Distribution of NK Cell Subsets and Their Phenotype in Infants Pre-ART Initiation and at 10 Months of Age
#51 - Vinh Dinh, United States
Impact of COVID-19 on Ugandan Children With and Without HIV
#52 - Mina Milad, United States
Guided Poster Tour 4 - Adolescents and HIV
IMARA SA: Piloting A Family-Based HIV/STI Prevention Package For South African Adolescent Girls and Young Women
#53 - Kate Merrill, United States
Ritonavir Concentrations in Hair Predict Virological Outcomes in HIV-Infected Adolescents With Virological Treatment Failure to Atazanavir/Ritonavir-Based Second-Line Treatment
#54 - Tariro Chawana, Zimbabwe
Using Narrative Films to Combat HIV-Related Stigma in Western Kenya: A Pilot Study of Adolescents Living With HIV And Their Caregivers
#55 - Brittany Mccoy, United States
Tenofovir, Lamivudine And Dolutegravir (TLD) Among Rural Adolescents in Zimbabwe, A Cautionary Tale
#56 - Vinie Kouamou, Zimbabwe
Feasibility and Acceptability of a Peer Youth Led Curriculum to Improve HIV Knowledge in Northern Tanzania: Resilience and Intervention Experience From the Perspective of Peer Leaders
#57 - Kalei Hosaka, United States
Trends in HIV Self-Testing Among Adolescent and Youth Populations Across Sub-Saharan Africa
#58 - Madison Ethridge, United States
Day 2 - Saturday, 17 July 2021
Session 5: Prevention of HIV in Adolescents and Advancing HIV Drug Evaluation in Pregnancy -
Long-Acting HIV Prevention in Adolescents: Possibilities and Challenges
Mina Hosseinipour, MD, MPH
University of North Carolina at Chapel Hill School of Medicine UNC Project Malawi, Malawi
Approaches to Enhance and Accelerate Study of New Drugs for HIV and Coinfections in Pregnancy
Shahin Lockman, MD, MSc
Harvard T.H. Chan School of Public Health, United States
Session 6: Oral Abstract Presentations - 3 Parallel Sessions -
Prevention of Perinatal Transmission and HIV-Exposed Uninfected Infants
More Frequent Viral Load Testing, With Point-Of-Care Tests Has No Impact on Viral Suppression in Postpartum HIV-Positive Women in a Randomized Controlled Trial in 2 Clinics in Johannesburg, South Africa
#19 - Lee Fairlie, South Africa
Usability and Feasibility of an HIV POC Viral Load to Identify Infants at High Risk of MTCT at Birth in Primary Healthcare Clinics in Mozambique
#20 - Bindiya Meggi, Mozambique
Key Clinical and Programmatic Outcomes of HIV-Exposed Infants in the International Epidemiology Databases to Evaluate AIDS Consortium
#21 - Andrew Edmonds, United States
Determinants of HIV-Free Survival in the Era of Lifelong Universal Antiretroviral Therapy (ART): Pooled Analysis of PEAWIL and IMPROVE Studies, Lesotho
#22 - Appolinaire Tiam, United States
Increased Infectious-Cause Hospitalization Among Infants Who Are HIV-Exposed Uninfected Compared to HIV-Unexposed
#23 - Kim Anderson, South Africa
Growth of Children HIV-Exposed and Uninfected in The Context of Lifelong Maternal Antiretroviral Therapy in Malawi
#24 - Gabriela Toledo, United Kingdom
Pediatric Care
There is No Substitute for Hard Work(Ing Dolutegravir): Outcomes of Single Drug Substitutions Among CALHIV Shifted to a Dolutegravir Antiretroviral Regimen in Mbeya and Mwanza, Tanzania
#25 - Jason Bacha, Tanzania
Pediatric ARV Optimization in a Real-World Setting: Dolutegravir Transition in Mozambique
#26 - Michelle M. Gill, United States
Co-Trimoxazole Prophylaxis for Children Born to Mothers With HIV: Predicted Impact of Different Strategies on Mortality Up To the Age of Two Years
#27 - Colette Smith, United Kingdom
Risk Factors for Post-Discharge Mortality Following Hospitalization for Severe Acute Malnutrition in Zimbabwe and Zambia
#28 - Mutsa Bwakura-Dangarembizi, Zimbabwe
Estimated Prevalence of Prior HIV Diagnosis Among Children Living With HIV in Eswatini, Lesotho, Malawi, Tanzania, Zambia, and Zimbabwe in the Population HIV Incidence Assessments (PHIA)
#29 - Chloe A. Teasdale, United States
A Costing Analysis of Index-Linked HIV Testing for Children and Adolescents in Zimbabwe
#30 - Arthi Vasantharoopan, United Kingdom
Adolescents
Rapid Antiretroviral NNRTI-Based Initiation among Youth Living with HIV Outcomes in the National Aids Program in Thailand
#31 - Sirinya Teeraananchai, Thailand
Optimizing Antiretroviral Treatment and Viral Suppression for Adolescents and Young People Living with HIV by Implementing Operation Triple Zero (OTZ) in Four States in Nigeria
#32 - Franklin Emerenini, Nigeria
Projecting Life Expectancy for Youth with Non-Perinatally- and Perinatally-Acquired HIV in the United States
#33 - Anne Neilan, United States
Hospitalisation Rates for Youth Living with Perinatally acquired HIV Transitioning to Adult Care
#34 - Sarah Johnson, United Kingdom
Increasing Capacity to Detect Neurocognitive Impairment among Adolescents and Young Adults with Perinatally Acquired HIV in Thailand: Validity of the NeuorScreen Tablet Application
#35 - Reuben N. Robbins, United States
Development of a Transition Readiness Score for Adolescents Living with Perinatally-Acquired HIV and Transitioning to Adult Care
#36 - Brian Zanoni, United States
Symposium - ViiV - Children and Challenges they Face... Our Calling: Optimizing Care in Pediatric HIV Treatment -
Symposium - ViiV - Children and Challenges they Face... Our Calling: Optimizing Care in Pediatric HIV Treatment
Session 7: Debate - Children Should be Prioritized for COVID-19 Vaccine Implementation -
Pro (Children Should Be Prioritized)
Marieke van der Zalm, MD, MSc (Clin Epi), PhD
Desmond Tutu TB Centre, South Africa
Con (Children Should Not Be Prioritized)
Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS
Children’s National Hospital, United States
Discussion
Session 8: COVID-19 in Children and Dolutegravir ART Transition in Pediatrics -
Situation Report: African COVID-19 Pandemic in Children
Shabir Madhi, MBBCh, FCPaeds, PhD
University of the Witwatersrand, South Africa
Progress – and Lack of Progress - on DTG Transition in Children in Africa
Peter Elyanu, MBChB, M.Med, PhD
Baylor College of Medicine Children Foundation, Uganda
Overview
Image
Pediatrics
Welcome

In the past decade, there has been impressive success in the prevention of mother-to-child HIV transmission. However, we have not eliminated the problem of pediatric HIV infection, and much work remains to be done. Research in pediatric, adolescent, and maternal HIV infections is often a neglected area at major scientific HIV conferences, yet it is critical to achieving an AIDS-free generation.

While we have highly effective interventions to prevent HIV transmission, implementation has been incomplete. In 2015, 1.8 million children were living with HIV and 150,000 were newly infected with the disease worldwide. Even with the continued scale-up of preventive services, it is estimated that 2 million children will need antiretroviral treatment (ART) in 2021. Unfortunately, children are substantially less likely than adults to be diagnosed, engaged in care, and to access life-saving ART.

The treatment of pediatric HIV infection, particularly of infants and young children, remains complex and problematic. Rapid growth and organ system maturation, as well as emotional and cognitive changes that occur across the developmental spectrum from infancy through adolescence, complicate drug development, and administration. Adherence outcomes in children have been less than robust and mental health and behavioral issues are emerging as critical to understand and address in order to ensure the success of long-term treatment. Additionally, while fewer infected children are being born, there are increasing concerns about the long-term impact of in utero and post-natal exposures to antiretroviral drugs for those children who escape HIV. Currently, an estimated 20% of all infants born in sub-Saharan Africa are exposed to HIV and antiretrovirals during pregnancy and the post-natal period.

Young people account for half of all new cases of HIV infection worldwide, with adolescent girls and young women disproportionately affected. In sub-Saharan Africa in 2015, three out of four newly infected adolescents aged 15–19 years were girls. Adolescents living with HIV have been a particularly difficult group to reach. HIV was the leading cause of death among adolescents living in Africa and the second-leading cause of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs struggle to reach and retain adolescents in care and adherence to treatment has special challenges.

The pediatric HIV cure agenda is an important emerging area of research. Early infant diagnosis is increasingly available globally, enabling the earlier identification of infection and provides new exciting opportunities to study acute infection in children and promising cure strategies. The HIV Pediatrics Workshop is the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers.

Workshop Chairs
General Information 
Unique Features
- Research in prevention and treatment of HIV in pregnant/lactating women, infants, children, and adolescents are discussed

- A good representation of all organizations involved in HIV treatment and care in HIV Pediatrics

- Special Session to address most recent research

- Young investigator awards for best oral presentation and best poster presentation.

- 6 dedicated poster walks

- 28 (mini-) oral presentations

- An extraordinary record of supporting scientific achievement as demonstrated in the success across the cascade from abstract presentation to publication
Who Should Attend?
- Researchers

- Clinicians

- Nurses

- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)
Meeting Objectives
This meeting aims at:

- Enhancing communication and encouraging new collaborations between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, youth and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.
- Understanding new long-acting prevention technologies and their application for prevention of HIV in adolescents.
- Evaluating effectiveness of and gaps in programs for prevention of perinatal HIV transmission and interventions to improve such programs.
- Sharing results from implementation science research on how to optimally implement proven interventions for prevention of perinatal HIV transmission and for pediatric and adolescent care and treatment in developing countries.
- Understanding complications of long-term HIV infection and its therapy, to enable improved management of HIV in children and adolescents.
Learning Objectives
After participating in this activity, participants will be able to:

- Describe the changing epidemiology of the pediatric HIV epidemic world-wide and the latest recommendations for pediatric and adolescent HIV treatment.
- Describe the impact of the COVID-19 pandemic on pediatric and maternal HIV programs and what we know about SARS-CoV-2 infection in African children.
- Summarize optimal treatment and management strategies of HIV infection in infants, children, adolescents, and pregnant and postpartum women.
- Describe potential complications of HIV and newer HIV treatments on children, adolescents, and pregnant/postpartum women.
- Summarize strategies to improve perinatal HIV prevention programs and to better understand continued risk for perinatal transmission in the ART era.
- Describe special issues related to HIV infection in adolescents and young people and new HIV prevention modalities and programming options for youth.
Practical Information 
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the workshop and post-workshop survey.
Language
The official language of the workshop is English.
Translation was not provided.
Enduring Materials
Enduring materials will be available here shortly after the conclusion of the workshop.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided that the speaker has given permission to do so.
Committees
Workshop Chairs 2021
Committee Members

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

We are proud to present the members of the committee:

  • Moherndran Archary, MBChB, DOH, FCPaeds, University of KwaZulu Natal, South Africa

  • Jason Brophy, MD - Children's Hospital of Eastern Ontario, Canada

  • Ellen Chadwick, MD - Childrens Memorial Hospital, United States

  • Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe

  • Polly Clayden - HIV i-Base, United Kingdom

  • Anita De Rossi, PhD - AIDS Reference Center, Italy

  • Marinella Della Negra, MD - Hospital Emilio Ribas, Brazil

  • Brian Eley, MD - Red Cross Children's Hospital, Department of Pediatrics, South Africa

  • Albert Faye, PhD - Denis Diderot University, Paris, France

  • Rashida Ferrand, MBBS, MRCP, MSc, DRM&H - London School of Hygiene & Tropical Medicine, United Kingdom

  • Tessa Goetghebuer, MD - Hôpital St Pierre, Belgium

  • Ali Judd, PhD, London School of Hygiene and Tropical Medicine, United Kingdom

  • Valériane Leroy, MD - Inserm, Paris, France

  • Chewe Luo, MD, PhD - UNICEF, United States

  • Dorothy Mbori-Ngacha, MBChB, MMed, MPH - United Nations Children's Fund, South Africa

  • Sharon Nachman, MD - SUNY Health Science Center Stony Brook, United States

  • Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States

  • Martina Penazzato, MD, MSc, PhD - WHO, Switzerland

  • Ann Petru, MD - UCSF Benioff Children's Hospital Oakland, United States

  • Jorge Pinto, MD, DSc - School of Medicine, Federal University of Minas Gerais, Brazil

  • Natella Rakhmanina, MD, PhD, FAAP, AAHIV - Elizabeth Glaser Pediatrics AIDS Foundation / Children's National Medical Center, United States

  • Theodore Ruel, MD - UCSF Benioff Children's Hospital San Francisco, United States

  • George Siberry, MD, MPH - United States Agency for International Development (USAID), United States

  • Lynda Stranix-Chibanda, MBChB, MMED - University of Zimbabwe, Zimbabwe

  • Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand

  • Graham Taylor, MD - Imperial College, United Kingdom

  • Claire Thorne, BA, MSc, PhD - University College London, United Kingdom

  • Marissa Vicari - International AIDS Society, Switzerland

  • Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States

The members of Scientific Committee are hand-picked by the Organizing Committee and the workshop secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

Support
Platinum Level
Gold level
Bronze Level

Support Our Initiative


Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals and community representatives involved in HIV and pediatrics.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Karin Siebelt at Karin@amededu.com or call +31 30 2307146.
 
Benefits of Support

By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
•    Symposium opportunities
•    Verbal acknowledgment during the program 
•    Discounted and complimentary registrations for your representatives
•    Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, program book, the streaming platform, and our website
•    Digital and printed advertising opportunities 
•    Social media shout-outs
•    Logo on the digital conference bag 
 
*Subject to the support level

Endorsers
Accreditation
Accreditation Statement

The International Workshop on HIV Pediatrics, Virtual, Netherlands, 16/07/2021-17/07/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.